Abstract:Objective To establish a preparation method of Norcantharidin tablets,and to detect content of Norcantharidin Tablets by using HPLC method.Methods Norcantharidin tablets were prepared with norcantharidin as the main drug,microcrystalline cellulose (MCC) and lactose as the fillers,sodium carboxymethyl starch (CMS-Na) as the disintegrating agent,polyvinylpyrrolidone K30(PVP-K30) as adhesive.Content of Norcantharidin tablets was detected with the method of HPLC;HPLC chromatographic conditions were: Spherigel ODS C18chromatographic column;mobile phase: acetonitrile - pH 3.1 phosphoric acid aqueous solution (10∶90) (V/V);the flow rate of 1.0 ml/min;column temperature 25℃;detection wavelength of 210 nm;sample quantity 20 μl.The factors A (starch),B (MCC) and C (CMS-Na) were selected,U7(73) uniform design was adopted,and preparation of Norcantharidin tablets was optimized through the dissolution index.Results HPLC standard curve equation: Y=925.374X-1778.8 (r=0.9999);linear range: 20~800 μg/ml.The intra-day precision RSD were 1.880%,0.172%,0.945%;inter-day precision RSD were 1.420%,1.126% and 1.468%.Coefficient of recovery in low,medium and high concentrations were separately (98.77±1.24)%,(100.08±1.14)%,(99.59± 0.58)% (n=5).Uniform design regression equation was K=-0.107-0.004A+0.017B-0.025C-0.0002B2+0.007C2(F=245.312,P<0.05);the optimized prescription composition was 10% starch,40% MCC,43% lactose and 7% CMS-Na;dissolution rate constant K was validated of (0.332±0.019)/min.Conclusion Norcantharidin tablets prepared with the optimized prescription preparation are with beautiful shape,good liquidity,lubricity and compression formability;HPLC method can effectively control the quality of tablets.
Lee YC,Lee LM,Yang CH,et al.Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells[J].Oncol Rep,2013,29(1):237-243.
Guan M,Zhou Y,Zhu QL,et al.N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy[J].Nanomedicine,2012,8(7):1172-1181.